Beneficial effects of cholesterol absorption inhibitor,ezetimibe on impaired endothelial function in patients with metabolic syndrome.

UMIN ID: UMIN000001305

Registered date:12/09/2008

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: Metabolic syndrome
• Date of first enrollment: 2008/09/01
• Target sample size: 60
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

Ezetimibe 10mg daily,during the study period.
control

Outcome(s)

• Primary Outcome: Rho-kinase activity FMD(flow-mediated dilation)
• Secondary Outcome: serum total and LDL cholesterol serum triglyceride cholesterol absorption marker adiponectin high sensitive CRP

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: 80years-old
• Gender: Male and Female
• Exclude criteria: 1) History of drug hypersensitivity to ezetimibe. 2) History of chronic heart failure. 3) Patients who have insulin therapy. 4) Patients who have severe liver dysfunction. Patients who have severe kidney dysfunction. 5) Patients who have secondary dyslipidemia or drug-induced dyslipidemia. 6) Pregnant or possibly pregnant patients. 7) Other patients deemed unsuitable as subjects of the study by the treating physician.

Related Information

• Primary Sponsor: Tohoku University Graduate School of Medicine EZET-trial group
• Source(s) of Monetary Support: None